Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: Results of a prospective feasibility study in advanced lung cancer in the okayama lung cancer study group trial 1002

Katsuyuki Hotta, Nagio Takigawa, Akiko Hisamoto-Sato, Eiki Ichihara, Kenichiro Kudo, Koji Uchida, Kayo Yanase-Nakamura, Hisaaki Tanaka, Yuka Kato, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Cisplatin can induce severe renal toxicity. However, the degree and pattern of hydration that is most efficient at preventing it have scarcely been formally evaluated. We here performed a prospective feasibility study of cisplatin-based chemotherapy with short-term low-volume hydration in advanced lung cancer. Methods: Chemo-nai{dotless}̈ve patients with advanced lung cancer and reserving renal function who were suitable for cisplatin use (≥60mg/m2 on Day 1) were eligible for this study. Two-and-a-half-liter hydration within (4.5h was investigated. The primary end point was the proportion of patients who underwent cisplatin-based chemotherapy without any Grade 2 or more renal toxicity in the first cycle. Results: A total of 46 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70mg/dl and the median cisplatin dose on Day 1 was 80mg/m2. In the first cycle, none of the patients developed Grade 2 or more creatinine toxicity, which met the primary endpoint. Four patients (9%) had Grade 1 toxicity, with a median worst creatinine score of 1.19mg/dl, but it disappeared rapidly. Creatinine toxicity was influenced by several clinical factors, including the performance status. Ten patients (22%) needed extra hydration during the first cycle, mainly due to gastrointestinal toxicity. However, all 10 were able to undergo further cycles of treatment. Thirty-two (86%) of the 37 patients who were assumed to be able to undergo further treatment at our institute received it in an outpatient setting. Conclusions: This study demonstrated prospectively the feasibility of short-term low-volume hydration.

Original languageEnglish
Article numberhyt128
Pages (from-to)1115-1123
Number of pages9
JournalJapanese Journal of Clinical Oncology
Volume43
Issue number11
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Feasibility Studies
Cisplatin
Lung Neoplasms
Prospective Studies
Drug Therapy
Creatinine
Kidney
Outpatients
Therapeutics

Keywords

  • Cisplatin
  • Hydration
  • Lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy : Results of a prospective feasibility study in advanced lung cancer in the okayama lung cancer study group trial 1002. / Hotta, Katsuyuki; Takigawa, Nagio; Hisamoto-Sato, Akiko; Ichihara, Eiki; Kudo, Kenichiro; Uchida, Koji; Yanase-Nakamura, Kayo; Tanaka, Hisaaki; Kato, Yuka; Tabata, Masahiro; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: Japanese Journal of Clinical Oncology, Vol. 43, No. 11, hyt128, 11.2013, p. 1115-1123.

Research output: Contribution to journalArticle

@article{35865dd5ca834fab912f75e13ca099d1,
title = "Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: Results of a prospective feasibility study in advanced lung cancer in the okayama lung cancer study group trial 1002",
abstract = "Objective: Cisplatin can induce severe renal toxicity. However, the degree and pattern of hydration that is most efficient at preventing it have scarcely been formally evaluated. We here performed a prospective feasibility study of cisplatin-based chemotherapy with short-term low-volume hydration in advanced lung cancer. Methods: Chemo-nai{dotless}̈ve patients with advanced lung cancer and reserving renal function who were suitable for cisplatin use (≥60mg/m2 on Day 1) were eligible for this study. Two-and-a-half-liter hydration within (4.5h was investigated. The primary end point was the proportion of patients who underwent cisplatin-based chemotherapy without any Grade 2 or more renal toxicity in the first cycle. Results: A total of 46 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70mg/dl and the median cisplatin dose on Day 1 was 80mg/m2. In the first cycle, none of the patients developed Grade 2 or more creatinine toxicity, which met the primary endpoint. Four patients (9{\%}) had Grade 1 toxicity, with a median worst creatinine score of 1.19mg/dl, but it disappeared rapidly. Creatinine toxicity was influenced by several clinical factors, including the performance status. Ten patients (22{\%}) needed extra hydration during the first cycle, mainly due to gastrointestinal toxicity. However, all 10 were able to undergo further cycles of treatment. Thirty-two (86{\%}) of the 37 patients who were assumed to be able to undergo further treatment at our institute received it in an outpatient setting. Conclusions: This study demonstrated prospectively the feasibility of short-term low-volume hydration.",
keywords = "Cisplatin, Hydration, Lung cancer",
author = "Katsuyuki Hotta and Nagio Takigawa and Akiko Hisamoto-Sato and Eiki Ichihara and Kenichiro Kudo and Koji Uchida and Kayo Yanase-Nakamura and Hisaaki Tanaka and Yuka Kato and Masahiro Tabata and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2013",
month = "11",
doi = "10.1093/jjco/hyt128",
language = "English",
volume = "43",
pages = "1115--1123",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy

T2 - Results of a prospective feasibility study in advanced lung cancer in the okayama lung cancer study group trial 1002

AU - Hotta, Katsuyuki

AU - Takigawa, Nagio

AU - Hisamoto-Sato, Akiko

AU - Ichihara, Eiki

AU - Kudo, Kenichiro

AU - Uchida, Koji

AU - Yanase-Nakamura, Kayo

AU - Tanaka, Hisaaki

AU - Kato, Yuka

AU - Tabata, Masahiro

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2013/11

Y1 - 2013/11

N2 - Objective: Cisplatin can induce severe renal toxicity. However, the degree and pattern of hydration that is most efficient at preventing it have scarcely been formally evaluated. We here performed a prospective feasibility study of cisplatin-based chemotherapy with short-term low-volume hydration in advanced lung cancer. Methods: Chemo-nai{dotless}̈ve patients with advanced lung cancer and reserving renal function who were suitable for cisplatin use (≥60mg/m2 on Day 1) were eligible for this study. Two-and-a-half-liter hydration within (4.5h was investigated. The primary end point was the proportion of patients who underwent cisplatin-based chemotherapy without any Grade 2 or more renal toxicity in the first cycle. Results: A total of 46 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70mg/dl and the median cisplatin dose on Day 1 was 80mg/m2. In the first cycle, none of the patients developed Grade 2 or more creatinine toxicity, which met the primary endpoint. Four patients (9%) had Grade 1 toxicity, with a median worst creatinine score of 1.19mg/dl, but it disappeared rapidly. Creatinine toxicity was influenced by several clinical factors, including the performance status. Ten patients (22%) needed extra hydration during the first cycle, mainly due to gastrointestinal toxicity. However, all 10 were able to undergo further cycles of treatment. Thirty-two (86%) of the 37 patients who were assumed to be able to undergo further treatment at our institute received it in an outpatient setting. Conclusions: This study demonstrated prospectively the feasibility of short-term low-volume hydration.

AB - Objective: Cisplatin can induce severe renal toxicity. However, the degree and pattern of hydration that is most efficient at preventing it have scarcely been formally evaluated. We here performed a prospective feasibility study of cisplatin-based chemotherapy with short-term low-volume hydration in advanced lung cancer. Methods: Chemo-nai{dotless}̈ve patients with advanced lung cancer and reserving renal function who were suitable for cisplatin use (≥60mg/m2 on Day 1) were eligible for this study. Two-and-a-half-liter hydration within (4.5h was investigated. The primary end point was the proportion of patients who underwent cisplatin-based chemotherapy without any Grade 2 or more renal toxicity in the first cycle. Results: A total of 46 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70mg/dl and the median cisplatin dose on Day 1 was 80mg/m2. In the first cycle, none of the patients developed Grade 2 or more creatinine toxicity, which met the primary endpoint. Four patients (9%) had Grade 1 toxicity, with a median worst creatinine score of 1.19mg/dl, but it disappeared rapidly. Creatinine toxicity was influenced by several clinical factors, including the performance status. Ten patients (22%) needed extra hydration during the first cycle, mainly due to gastrointestinal toxicity. However, all 10 were able to undergo further cycles of treatment. Thirty-two (86%) of the 37 patients who were assumed to be able to undergo further treatment at our institute received it in an outpatient setting. Conclusions: This study demonstrated prospectively the feasibility of short-term low-volume hydration.

KW - Cisplatin

KW - Hydration

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84887072071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887072071&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt128

DO - 10.1093/jjco/hyt128

M3 - Article

C2 - 24082005

AN - SCOPUS:84887072071

VL - 43

SP - 1115

EP - 1123

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

M1 - hyt128

ER -